Scilex Holding (SCLX) Q1 2026 earnings summary

Executive summary

• Net revenue for Q1 2026 was $8.6 million, up from $5.0 million in Q1 2025, driven by higher ZTlido sales and increased contract revenue from Vivasor.

• Net loss widened to $45.7 million from $26.1 million year-over-year, reflecting higher operating expenses and significant non-cash losses.

• The company continues to focus on non-opioid pain management products, with ZTlido, ELYXYB, and GLOPERBA as commercial products and a late-stage pipeline including SEMDEXA, SP-103, and SP-104.

• Management has raised substantial doubt about the company's ability to continue as a going concern due to negative working capital and low cash reserves.

Financial highlights

• Net revenue increased by $3.6 million year-over-year, primarily from ZTlido and Vivasor contract revenue.

• Cost of revenue rose to $4.4 million from $1.4 million, mainly due to higher shipping and product costs.

• Research and development expenses increased to $3.2 million, reflecting higher costs for SP-102 and KDS2010 development.

• Selling, general, and administrative expenses rose to $31.0 million, up $2.9 million, driven by advisory, facility, and contract service costs.

• Intangible amortization expense doubled to $2.1 million, mainly from Datavault license amortization.

• Significant non-cash items included a $25.7 million gain on warrant derivative liabilities and a $21.8 million loss on the Scilex-St. James loan compound derivative.

• Unrealized losses on digital assets and equity method investments were $18.1 million and $31.7 million, respectively, offset by a $42.3 million realized gain on Datavault investment sales.

• Cash and cash equivalents at quarter-end were $3.4 million.

Outlook and guidance

• Management expects continued investment in marketing and R&D, requiring substantial additional funding.

• Plans to finance operations through equity, debt, collaborations, or strategic transactions; success depends on future sales of ZTlido, ELYXYB, and GLOPERBA.

• Substantial doubt remains about the ability to continue as a going concern for the next 12 months.